CREMA Achievement Highlights

Mid-term progress report for the period 1 January 2014 – 30 June 2016
## Contents

From the Program and Scientific Directors ........................................................................................................ 2

CREMA at a glance .............................................................................................................................................. 3

- Operations ..................................................................................................................................................... 3

Summary of outputs ............................................................................................................................................... 3

Our people ......................................................................................................................................................... 4

- Node directors and Chief Investigators ....................................................................................................... 4

- Node directors and Chief Investigators (cont.) .......................................................................................... 5

- Associate Investigators ............................................................................................................................... 6

- Early Career Researchers ............................................................................................................................ 6

International Speaker and academic visit ........................................................................................................ 7

CREMA creates real impact ............................................................................................................................... 7

- Policy engagement ....................................................................................................................................... 7

- Expert Advice ............................................................................................................................................... 8

- Media engagement ....................................................................................................................................... 9

Early Career Researcher Achievements ........................................................................................................... 11

- PhD and Masters Completions .................................................................................................................... 11

- Post-doctoral Fellowships .......................................................................................................................... 11

- Awards ......................................................................................................................................................... 11

Summary of program performance indicators ............................................................................................... 13

- Peer Reviewed Journal Publications .......................................................................................................... 13

- Presentations ................................................................................................................................................ 18

- Books and book chapters ............................................................................................................................ 23

- Reports ......................................................................................................................................................... 23

- Funding leveraged ....................................................................................................................................... 23

Contact ............................................................................................................................................................ 24
We are pleased to present to you the interim achievements report of the NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA). This report describes the achievements of the Centre from the commencement of the program in January 2014 until 30 June 2016.

The mission of CREMA is to improve health by providing robust evidence relevant to the quality use of medicines as people age. The CREMA develops innovative research methods relating to medicine use, to address key clinical and policy research questions and leverage from its growing infrastructure of linked routinely collected health data.

The aims of CREMA are to:

1. Generate quantitative evidence on the real-world use, safety, costs and cost-effectiveness of specific medicines in relation to ageing and disseminate this evidence through high quality peer-reviewed publications and presentations
2. Work with agencies to define key areas of research focus and to embed CREMA evidence in policy formulation, evaluation and decision-making.
3. Build national workforce capacity and processes in pharmacoepidemiology research and policy translation.
4. Establish a robust program governance infrastructure in order to ensure highest level of performance for CREMA

As you will see from this interim report, the expertise and evidence arising from CREMA's work is already creating great impact on clinical and pharmaceutical policy and practice decisions.

A notable achievement has been the high number of peer review papers in leading journals and numerous presentations at key scientific and policy meetings which reinforces our commitment to communication of the work of CREMA to enhance its translation and impact.

We are proud of the support and development of early career researchers offered as part of CREMA as a commitment to building research capacity in this field. Of particular note is the research work involved in the publication “The crux of the matter: Did the ABC’s Catalyst program change statin use in Australia?” published in the Medical Journal of Australia in 2015. This paper exemplified many of the elements we are hoping to achieve in CREMA. The work was led by an early career researcher with input and expertise from senior researchers across the CREMA research nodes. The research itself deals with the real world impact of media on utilisation of an important class of medicines using strong science to provide key insights into the impact on human health and quality care. As Directors we were very proud of the fact that this work, supported by CREMA, received the 2015 Medical Journal of Australia & MDA National Prize for Excellence in Medical Research.

We would like to thank our collaborators and staff members and students for making this CREMA the success story that it has become in such a short time.

Professor Andrew McLachlan, CREMA Program director

Professor Sallie-Anne Pearson, CREMA Scientific director
CREMA at a glance

Operations

CREMA is administered through the Faculty of Pharmacy at the University of Sydney and comprises collaborations across four participating centres (nodes): Australian National University (ANU), University of Western Australia (UWA), The University of Technology, Sydney (UTS), and most recent member of the CREMA family, The University of NSW (UNSW) which joined the program in 2016. CREMA has a well-established governance structure headed by the Executive, comprising:

- Program Director and Node Director USYD – Andrew McLachlan
- Scientific Director and Node director UNSW – Sallie-Anne Pearson
- Node Director UWA – David Preen
- Node Director ANU – Emily Banks
- Node Director UTS – Rosalie Viney
- Research Program Manager – Monika Dzidowska

CREMA’s activities are guided by a strategic plan and an annual operations plan. CREMA’s central office at the University of Sydney focuses on development and coordination of central capacity building activities as well as communications between nodes and with external stakeholders. These activities include the following:

- Travel and Training Support Scheme
- PhD scholarships scheme
- Regular newsletters
- Concept development workshops and research planning meetings

To date CREMA has awarded more than $23,000 in travel and training support, and has granted five top up scholarships, one full scholarship and one partial scholarship to PhD students studying at CREMA’s nodes.

Summary of outputs

<table>
<thead>
<tr>
<th>Category</th>
<th>Count/Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total funding leveraged:</td>
<td>$2,848,650</td>
</tr>
<tr>
<td>Journal articles</td>
<td>64</td>
</tr>
<tr>
<td>Books, book chapters and reports</td>
<td>4</td>
</tr>
<tr>
<td>Presentations</td>
<td>74</td>
</tr>
<tr>
<td>Post-graduate students supported by grant</td>
<td>10</td>
</tr>
<tr>
<td>Post-doctoral researchers and research staff supported by grant</td>
<td>12</td>
</tr>
</tbody>
</table>
Our people

Node directors and Chief Investigators

**Program director:**
Prof. Andrew McLachlan  
Faculty of Pharmacy  
The University of Sydney  

**Scientific Director and UNSW Node Director:**
Prof. Sallie-Anne Pearson  
Medicines Policy Research Unit  
Centre for Big Data Research in Health  
University of New South Wales  
[https://cbdrh.med.unsw.edu.au/people/dr-sallie-pearson](https://cbdrh.med.unsw.edu.au/people/dr-sallie-pearson)

**ANU Node Director:**
Prof. Emily Banks  
National Centre for Epidemiology and Population Health Research, School of Population Health  
Australian National University  

**UTS Node Director:**
Prof. Rosalie Viney  
Centre for Health Economics Research and Evaluation  
University of Technology, Sydney  

**UWA Node Director:**
Prof. David Preen  
Centre for Health Services Research  
School of Population Health,  
The University of Western Australia  
Node directors and Chief Investigators (cont.)

Prof. Nicholas Buckley
Discipline of Pharmacology
The University of Sydney

Assoc.Prof. Timothy Dobbins
National Drug & Alcohol Research Centre
University of New South Wales
https://ndarc.med.unsw.edu.au/people/dr-timothy-dobbins

Prof Christopher Etherton-Beer
School of Medicine and Pharmacology
The University of Western Australia

Prof. David Henry
Institute of Health Policy, Management and Evaluation
University of Toronto
http://ihpme.utoronto.ca/faculty/david-henry/

Prof. David Le Couteur
Concord Clinical School
The University of Sydney
Associate Investigators

Prof. Darrell Abernethy  
Johns Hopkins University, USA  
http://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/abernethy.html

Prof. Michal Abrahamowicz  
McGill University Health Centre Research Institute, Canada  
http://www.med.mcgill.ca/epidemiology/abrahamowicz/

Prof. Fiona Blyth (USYD)  
The University of Sydney  

Prof. Andrew Dawson (USYD)  
The University of Sydney  

Prof. Marion Haas (UTS)  
University of Technology, Sydney  
http://www.uts.edu.au/staff/marion.haas

Dr Danijela Gnjidic (USYD)  
The University of Sydney  

Prof. Sarah Hilmer (USYD)  
The University of Sydney  

Early Career Researchers

Ms Bianca Blanch (USYD)  
Dr Tom Longden (UTS)

Dr Jonathan Brett (UNSW)  
Ms Bernie Morris (ANU)

Dr Rose Cairns (USYD)  
Mr Atheer Nassir (USYD)

Mr Benjamin Daniels (UNSW)  
Ms Ellie Paige (ANU)

Mr Richard De Abreu Lourenco (UTS)  
Dr Bonny Parkinson (UTS)

Ms Alice George (ANU)  
Ms Smriti Raichand (UNSW)

Dr Natasha Gisev (UNSW)  
Dr Rebecca Reeve (UTS)

Mr Philip Haywood (UTS)  
Ms Andrea Schaffer (UNSW)

Dr Grace Joshy (ANU)  
Ms Karla Seaman (UWA)

Dr Emily Karanges (UNSW)  
Dr Gabriella Willis (UWA)

Dr Anna Kemp-Casey (UWA)  
Dr Naomi Van Der Linden

Ms Tina Lavin (UWA)  
Dr Fei Li Zhao (UTS)

Dr Derrick Lopez (UWA)
International speaker and academic visit

In May 2016 the CREMA research node at the UNSW hosted the visit of Professor David Juurlink from the Departments of Medicine, Pediatrics, and Health Policy, Management, and Evaluation, University of Toronto and Sunnybrook Research Institute. Professor Juurlink presented an excellent seminar on “Studying drug safety in the real world” and had the opportunity to meet and interact with CREMA early career researches.

CREMA creates real impact

CREMA’s researchers frequently engage with stakeholders both internally and with those external to the University sector in order to facilitate translation of their research findings into policy and practice. We believe that this is crucial in creating a positive impact on the outcomes for the Australian community. CREMA achieves this through providing expert advice, involvement on expert panels, committees and working groups, engaging the media in dissemination of the latest research findings and conducting workshops and other educational activities. All CREMA researchers are involved in stakeholder engagement on many levels. Highlighted below are some of stakeholder engagement activities since commencement of CREMA.

Policy engagement

Commonwealth Department of Health

The cardiovascular disease (CVD) variation team led by Emily Banks published work on the Absolute Risk of CVD in the Australian population in the MJA on 2nd May 2016. The work included data on large shortfalls in preventive treatment for CVD. It has facilitated significant policy stakeholder engagement regarding evaluation and improvement of CVD assessment, including the Commonwealth Department of Health and the Heart Foundation. There was significant media attention associated with the release of these findings including at least 24 distinct media items.

The team has also met with the Commonwealth Department of Health for an Aboriginal Health staff seminar and policy roundtable. The sessions were attended by members of the PM&C, MBS Review Committee and senior Departmental staff. All participants were keen to hear about research in this area and good discussion was facilitated in regards to policy implementation for future research.
Absolute CVD risk assessment implementation and evaluation workshops hosted in conjunction with the Indigenous Health Division are planned for later in 2016.

**Working towards data access for research purposes**

Professors David Preen and Sallie Pearson were invited to give evidence to the Federal Senate Select Committee on Health about Commonwealth data access for researchers, during the Committee’s in December 2015. The hearing resulted in the Sixth Interim Report entitled: “Big health data: Australia’s big potential” released on 4 May 2016, in which the committee concluded that Australia had the potential to significantly benefit from improved data linkage arrangements and urged the government to “seize this valuable opportunity to improve individual patient outcomes and raise the overall standard of healthcare in Australia.” The committee made a number of specific recommendations which would facilitate access to and linkage of Commonwealth data for research purposes. Details of the report are available on [http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Health/Health/Sixth_Interim_Report](http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Health/Health/Sixth_Interim_Report)

**Capital Health Network and ACT Heart Foundation**

The CVD variation team led by Emily Banks developed and delivered a workshop on *Absolute cardiovascular disease risk: current national guidelines and new evidence on assessment and management* hosted by the Capital Health Network and the Heart Foundation ACT. The session was aimed at General Practitioners and presented research evidence and ways in which to address shortfalls in CVD absolute risk assessment and management. The workshop was well-received by participants and will be repeated in the future.

**Expert advice**

CREMA’s Chief Investigators and Associate Investigators are active members and chairs of national and state drug policy committees and are frequently called upon provide input into policy and research planning as well as to provide training and mentoring. CREMA also promotes involvement of Early Career Researchers in many of these activities including providing consultations, and committee participation. Our involvement includes the following committees:

- NPS MedicineWise
- Therapeutic Goods Authority (TGA)
- National Health Performance Authority
- Cancer Australia
- Data Analysis and Development, Health Analytics Branch, DOH
- Productivity Commission
- Academy of Social Sciences Australia
- Queensland Network of Alcohol and Other Drug Agencies (QNADA)
- Pharmaceutical Society of Australia
- Pharmaceutical Benefits Advisory Committee (PBAC)
• Drug Utilisation Sub Committee (DUSC)
• Advisory Committee on Safety of Medicines
• Advisory Committee on Safety of Vaccines
• Department of Human Services External Request Evaluation Committee (EREC)
• The NSW Population & Health Services Research Ethics Committee

Media engagement

Statins + Catalyst program

Ms Andrea Schaffer (pictured right), Professor Emily Banks, Professor Nicholas Buckley, Associate Professor Timothy Dobbins and Professor Sallie-Anne Pearson (pictured left) published a paper in June 2015, entitled “The crux of the matter: Did the ABC’s Catalyst program change statin use in Australia?”. The paper described a study on statin use in Australia and demonstrated that over 60,000 Australians cut back on or stopped taking statins in the eight months after the Catalyst program “The Heart of the Matter” aired. The ABC has since removed the Catalyst episode from public view. The paper attracted considerable media attention. The researchers were awarded the 2015 Medical Journal of Australia & MDA National Prize for Excellence in Medical Research for their study. The prize was presented at the Australian Medical Association’s 2016 National Conference in Canberra. The research attracted considerable media attention. Some examples are:

“Australians cut back on or stopped taking statins following ABC Catalyst story, researchers find” ABC NEWS online, 15 June 2015.


“60,000 fewer patients took vital statin drugs following ABC's Catalyst program” The Guardian online, 15 June 2015.

http://www.theguardian.com/media/2015/jun/14/60000-fewer-patients-took-vital-statin-drugs-following-abcs-catalyst-program


Absolute Risk of CVD

The study on Absolute Risk of CVD in the Australian population published in the Medical Journal of Australia on 2nd May 2016 facilitated significant policy engagement of stakeholders, including the
Commonwealth Department of Health and the Heart Foundation as well as significant media attention including at least 24 distinct media items, examples include:

http://www.sbs.com.au/topics/life/health/article/2016/05/02/one-five-australians-risk-heart-attack-or-stroke


Prescribed opioid use and outcomes

This work is an ecological study exploring opioid use and related harms (hospitalisations and deaths) from 1992. It was published in the *British Journal of Clinical Pharmacology* (2014) and authors Bianca Blanch and Sallie-Anne Pearson were interviewed by David Brill who wrote a story in Australian Doctor:

“Opioid script restriction may hurt patients” Australian Doctor, 11 July 2014.


Antidepressant use in Children

Emily Karanges was interviewed for the article: ‘*Why students are packing Prozac in their lunch boxes.*’ By Dannielle Miller. The Daily Telegraph (online). January 31, 2016.

Upscheduling of alprazolam

This study was conducted in collaboration with the NHMRC Translational Australian Clinical Toxicology program and the NSW Poisons Information Centre. It investigated the changes in alprazolam use and intentional poisonings following rescheduling from S4 to S8 by the TGA in 2014.


Andrea Schaffer was interviewed in the Health Report [http://www.abc.net.au/radionational/programs/healthreport/rescheduling-alprazolam/7658248](http://www.abc.net.au/radionational/programs/healthreport/rescheduling-alprazolam/7658248)
Early Career Researcher achievements

One of CREMA’s goals is to build national workforce capacity and processes in pharmacoepidemiology research and policy translation and mentoring Early Career Researchers (ECRs) is crucial in achieving these goals. CREMA directly supports 11 Early Career Researchers. Many more are mentored through involvement in collaborative projects. Below are highlights of our ECRs’ achievements.

PhD and Masters completions

- Ellie Paige completed her PhD on the topic of “Antidepressant medication use and weight change” (Sept 2015). She also received an award from the Australasian Epidemiological Association (AEA) for conference travel to present her research on antidepressant use at the AEA conference in New Zealand (2014).
- Dr Manonita Gosh completed her PhD on “Differentiating patterns of stimulant medication treatment for ADHD in Western Australia”.
- Dr Gabriella Willis completed her MPH research thesis and was awarded a pass with distinction on the topic “The impact of influenza vaccination in young children in metropolitan Western Australia”.
- Carole Harris was awarded her MPhil in 2014, entitled ‘Measuring treatment patterns and outcomes of HER2 positive breast cancer using clinical trials and routine clinical care.

Post-doctoral fellowships

- Dr Alison Pearce was the recipient of a prestigious Chancellor’s Postdoctoral Fellowship after completing her post-doctoral fellowship at the National Cancer Registry in Ireland

Awards

- Richard De Abreu Lourenco was the UTS Business School winner of the 3 Minute Thesis Competition, for a presentation that was based on a chapter of his PhD that examines the value to patients of different modes of administration of rheumatoid arthritis medications.
- Andrea Schaffer was awarded The Stanley A. Edlavitch Award, International Conference on Pharmacoepidemiology – best abstract submitted by a student/post-doc. Andrea was also awarded Best Presentation’ at the University of Sydney Faculty of Pharmacy 2015 Annual Postgraduate Conference Andrea Schaffer ‘Investigating the impact of the ABC Catalyst program on statin use and discontinuation.
• Jonathan Brett won the National Health and Medical Research Council Research Excellence Award – Gustav Nossal Award.

• Grace Joshy was awarded the Victorian Centre for Biostatistics (ViCBiostat) Visiting Fellowship 2015. ViCBiostat is led by senior academic biostatisticians from the Murdoch Children’s Research Institute (MCRI), Monash University and The University of Melbourne. As part of this fellowship, Grace was an invited speaker at the VicBiostat Seminar, Melbourne, October 2015. She presented the following seminar: Joshy G, Clements M, Banks E, Lowe A, Tickle L, Armstrong B. “Five-year mortality predictors in Australian Men 45 years of age and older.” Grace also spent two weeks in Melbourne working with the VicBiostat team.

• Philip Haywood was the winner of the Implementation Science Community of Practice award at the TCRN Session at the Cancer Innovations Conference.

• Fei-Li Zhao’s paper “Burden of Disease Studies in the Asia-Pacific Region: Are There Enough Being Performed to Provide for Evidence-Based Health Policy?” Vol. 2 Issue 1 (2013) 152-159 was selected as the best article for the ViHRI Excellent Article Award and the award will be presented at ISPOR 7th Asia-Pacific Conference in Singapore.
Summary of program performance indicators

Peer reviewed journal publications

Total number of journal publications: 64

2016


Gosh M, Fisher C, Preen DB, Holman CDJ. It has to be fixed: a qualitative inquiry into perceived ADHD behaviour among affected individuals and parents in Western Australia. *BMC Health Services...*


**2015**


Blanch B, Buckley N, Mellish L, Dawson A, Haber P, Pearson S. Harmonizing post-market


2014


**Presentations**

Total number of presentations: 74

**Invited presentations**


Karanges E. Psychopharmacoepidemiology in Australia, *University of Sydney Honours program (Drugs and Behaviour)*. April 2016.

Pearson S. The big data revolution: What does it mean for Australian pharmacoepidemiology research? *Woolcock Institute for Medical Research*, University of Sydney 2016; Sydney Australia.

Schaffer A. Interrupted time series analysis of the impact of up-scheduling alprazolam as a “Controlled Drug” on benzodiazepine prescribing, dispensing and poisonings. *UNSW Biostatistics Seminar*, UNSW April 2016.

Korda R. Keynote presentation. “Modifiable risk factors of CVD” at the Cardiovascular Health Research Symposium in Canberra on 5th May 2016, organised by Heart Foundation ACT.


McLachlan A. *Drug interactions that matter* – plenary presentation at the Pharmaceutical Society of Australia Annual Therapeutic Update (ATU) March 2015

Pearson S. Building capacity in pharmacoepidemiology research in Australia. *St Vincent’s Hospital Therapeutics Centre. University of NSW* 2015; Sydney Australia.


Pearson S. *Senate Select Committee on Health*. 2015 Sydney, Australia.

Preen D. *Senate Select Committee on Health*. 2015 Sydney, Australia.

Schaffer A. The crux of the matter: Did the ABC’s Catalyst program change statin use in Australia? *MURA Sept 2015*.


Preen D. Health Services Research with Linked Large Existing Electronic Administrative Registries IMEHP S Research Seminar – University of Vienna, Austria. Oct 2014

Joshy G. Invited Lecture: “Cardiovascular Disease Epidemiology”. Centre for Research in Therapeutic Solutions, University of Canberra, 23 June 2014.

**Conference presentations**

**2016**


Daniels B, Pearson S. Tracking trastuzumab (H) therapy in early through late stage HER2-positive breast cancer (HER2BC) in Australia: A national, retrospective cohort study. *International Conference on Pharmacoepidemiology 2016*, Dublin Ireland.


Karanges, E. Prescription opioid use and harms in Australia: If you can’t measure it, you can’t manage it! *Toxicology and Poisons Network Australasia (TAPNA) conference*. 2016. Brisbane, Australia.


Van Der Linden N, ‘Cost-utility of sentinel lymph node biopsy in patients with cT1-T2N0 oral cancer’ *ISPOR Australia Chapter Workshop, Contemporary Economic Modelling – State of the Art, Sydney, 2016.*

2015


Haywood P. Pricing in the new oncology era may result in error UTS Business School PhD Conference, November 2015 Sydney.


Kemp A, Roughhead E, Saunders C, Boyle F, Bulsara M, Preen D. Switching between endocrine therapies for primary breast cancer: how often and when does it happen in real world practice? International Conference for Pharmacoepidemiology, August 2015 Boston, USA.


2014


Ghosh M, Holman CD, Preen DB. Explaining ethnic differences in the use of stimulant medications for ADHD. 4th World Congress on ADHD. 2014 Milan, Italy.


Preen D. Health Services Research with Linked Large Existing Electronic Administrative Registries. IMEHPS Research Seminar – University of Vienna. 2014, Vienna, Austria.


Rankin N, McGregor D, Travena L, White K, Butow P, Phillips J, York S, Pearson S. A systematic approach to closing evidence gaps in cancer care. 3rd Annual NHMRC Research Translation Faculty Symposium, Achieving better health outcomes for Australians living with chronic conditions through more effective research translation. 2014; Melbourne, Australia.


Books and book chapters


Reports


Funding leveraged

Total funding leveraged: $2,848,650

<table>
<thead>
<tr>
<th>Funding organisation</th>
<th>Title/Brief description</th>
<th>Amount</th>
<th>Funding duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Sydney</td>
<td>Low value medical services and prescribing practices in cancer care: towards a comprehensive framework for quantifying waste in Australia and beyond</td>
<td>$150,000.00</td>
<td>1 year</td>
</tr>
<tr>
<td>SPARC Implementation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Cancer) Funding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University of Sydney</td>
<td>Investigating psychotropic medicine use in Australia</td>
<td>$49,700.00</td>
<td>1 year</td>
</tr>
<tr>
<td>SPARC Implementation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(BMRI) Funding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sydney Catalyst</td>
<td>Do changes to chemotherapy dose and increased toxicity explain poorer survival outcomes in advanced cancer patients with systemic inflammation?</td>
<td>$50,000.00</td>
<td>1 year</td>
</tr>
<tr>
<td>Seed Funding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant Provider</td>
<td>Description</td>
<td>Amount</td>
<td>Duration</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>NHMRC Project Grant</td>
<td>Measuring low-value health care for targeted policy action</td>
<td>$806,000.00</td>
<td>3 years</td>
</tr>
<tr>
<td>NHMRC Project Grant</td>
<td>Improving decisions about the funding of high cost cancer medicines in Australia</td>
<td>$549,000.00</td>
<td>3 years</td>
</tr>
<tr>
<td>CIHR Project Grant</td>
<td>New statistical methods for cohort studies of adverse effects of medications</td>
<td>$753,035.00</td>
<td>5 years</td>
</tr>
<tr>
<td>Medibank Health Solutions Grant</td>
<td>Evaluation of an Integrated Healthcare Services Model of Care.</td>
<td>$343,008.00</td>
<td>2 years</td>
</tr>
<tr>
<td>Fremantle Hospital Research Fund</td>
<td>Health Service utilisation by marginalised street populations study.</td>
<td>$67,907.00</td>
<td>1 year</td>
</tr>
<tr>
<td>Australasian Self Medication Industry</td>
<td>A project using discrete choice experiments to explore the effect of S3 advertising on decisions about over the counter pharmaceutical products.</td>
<td>$80,000.00</td>
<td>1 year</td>
</tr>
</tbody>
</table>

**Contact**

CREMA Central office & Sydney Node  
The University of Sydney NSW 2006  
Phone: +61 2 9351 6131  
E-mail: monika.dzidowska@sydney.edu.au